Company intelligence / Profile preview

MicroPharm Limited

Newcastle Emlyn, Carmarthenshire, United Kingdommicropharm.org ↗

Ownership: Private
Employees: ~51
Development stage: Commercial

Overview

MicroPharm develops and manufactures immunotherapeutic products—primarily ovine polyclonal antibody-based anti-toxins—for the treatment of acute life-threatening emergencies such as snakebites. The company currently produces two anti-vemon therapeutics for the European common adder and the West African carpet viper. It has expanded manufacturing capacity to support growth as a leading supplier to Europe and Africa.

Therapeutic areas: OtherInfectious Diseases
Modalities: Ovine polyclonal antibodies (immunotherapeutics)
Industry: Biotech

Drug pipeline

7 assets

Favirept

Preclinical

6 more assets in the full pipeline.

Request access →

Partnerships

Supported by Welsh Government investment for expansioncollaboration with Ig-Innovations Ltd for antibody supply.

Beyond the preview

Go deeper on MicroPharm Limited.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MicroPharm Limited.

Explore the full profile